NCT06905054View on ClinicalTrials.gov

Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

April 15, 2025

Primary Completion Date

March 30, 2028

Study Completion Date

July 1, 2028

Conditions
Primary Sclerosing CholangitisLiver Transplant, ComplicationsPSCBiliary Strictures
Interventions
DRUG

Fenofibrate (drug)

Once daily fenofibrate for 36 months

DIAGNOSTIC_TEST

Blood draw for the laboratory assessment

Serum assessments will be performed every 3 months during the study period

DIAGNOSTIC_TEST

MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA)

Participants will undergo a quantitative gadoxetate-enhanced MRI and MRCP at baseline, and at 12 months and 36 months of trial participation.

Trial Locations (1)

85259

RECRUITING

Mayo Clinic in Arizona, Scottsdale

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT06905054 - Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation | Biotech Hunter | Biotech Hunter